|
1
|
Gluz O, Liedtke C, Gottschalk N, Pusztai
L, Nitz U and Harbeck N: Triple-negative breast cancer-current
status and future directions. Ann Oncol. 20:1913–1927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wahba HA and El-Hadaad HA: Current
approaches in treatment of triple-negative breast cancer. Cancer
Biol Med. 12:106–116. 2015.PubMed/NCBI
|
|
6
|
Mayer IA, Abramson VG, Lehmann BD and
Pietenpol JA: New strategies for triple-negative breast
cancer-deciphering the heterogeneity. Clin Cancer Res. 20:782–790.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seiwert TY, Burtness B, Mehra R, Weiss J,
Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et
al: Safety and clinical activity of pembrolizumab for treatment of
recurrent or metastatic squamous cell carcinoma of the head and
neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial.
Lancet Oncol. 17:956–965. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Plimack ER, Bellmunt J, Gupta S, Berger R,
Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF and O'Donnell PH:
Safety and activity of pembrolizumab in patients with locally
advanced or metastatic urothelial cancer (KEYNOTE-012): A
non-randomised, open-label, phase 1b study. Lancet Oncol.
18:212–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chow LQM, Haddad R, Gupta S, Mahipal A,
Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al:
Antitumor activity of pembrolizumab in biomarker-unselected
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion
cohort. J Clin Oncol. 34:3838–3845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to Neoadjuvant therapy and Long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-line nivolumab in stage IV or recurrent non-small-cell
lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Diem S, Hasan Ali O, Ackermann CJ, Bomze
D, Koelzer VH, Jochum W, Speiser DE, Mertz KD and Flatz L: Tumor
infiltrating lymphocytes in lymph node metastases of stage III
melanoma correspond to response and survival in nine patients
treated with ipilimumab at the time of stage IV disease. Cancer
Immunol Immunother. 67:39–45. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hugo W, Zaretsky JM, Sun L, Song C, Moreno
BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G,
et al: Genomic and transcriptomic features of response to Anti-PD-1
therapy in metastatic melanoma. Cell. 165:35–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Connor AA, Denroche RE, Jang GH, Timms L,
Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA,
Borozan I, et al: Association of distinct mutational signatures
with correlates of increased immune activity in pancreatic ductal
adenocarcinoma. JAMA Oncol. 3:774–783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Van Allen EM, Miao D, Schilling B, Shukla
SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger
SM, et al: Genomic correlates of response to CTLA-4 blockade in
metastatic melanoma. Science. 350:207–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
R Core Team, . R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2012, ISBN 3-900051-07-0. http://www.R-project.org/
|
|
28
|
RStudio Team, . RStudio: Integrated
development for R. RStudio, Inc.; Boston, MA: 2015, http://www.rstudio.com/
|
|
29
|
Nagy A, Lanczky A, Menyhart O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yarchoan M, Johnson BA III, Lutz ER,
Laheru DA and Jaffee EM: Targeting neoantigens to augment
antitumour immunity. Nat Rev Cancer. 17:5692017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Finotello F and Trajanoski Z: Quantifying
tumor-infiltrating immune cells from transcriptomics data. Cancer
Immunol Immunother. 67:1031–1040. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bagley SJ, Hwang WT, Brem S, Linette GP,
O'Rourke DM and Desai AS: RNA-seq for identification of
therapeutically targetable determinants of immune activation in
human glioblastoma. J Neurooncol. 141:95–102. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan S, Zhan Y, Chen X, Wu B and Liu B:
Bladder cancer exhibiting high immune infiltration shows the lowest
response rate to immune checkpoint inhibitors. Front Oncol.
9:11012019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Havel JJ, Chowell D and Chan TA: The
evolving landscape of biomarkers for checkpoint inhibitor
immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sharma P, Retz M, Siefker-Radtke A, Baron
A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, et
al: Nivolumab in metastatic urothelial carcinoma after platinum
therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial.
Lancet Oncol. 18:312–322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carbognin L, Pilotto S, Milella M, Vaccaro
V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D,
Chilosi M, et al: Differential activity of nivolumab, pembrolizumab
and MPDL3280A according to the tumor expression of programmed
death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma,
lung and genitourinary cancers. PLoS One. 10:e01301422015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watson IR, Takahashi K, Futreal PA and
Chin L: Emerging patterns of somatic mutations in cancer. Nat Rev
Genet. 14:703–718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gubin MM, Zhang X, Schuster H, Caron E,
Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et
al: Checkpoint blockade cancer immunotherapy targets
tumour-specific mutant antigens. Nature. 515:577–581. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schon K and Tischkowitz M: Clinical
implications of germline mutations in breast cancer: TP53. Breast
Cancer Res Treat. 167:417–423. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Silwal-Pandit L, Vollan HK, Chin SF, Rueda
OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S,
Børresen-Dale AL, et al: TP53 mutation spectrum in breast cancer is
subtype specific and has distinct prognostic relevance. Clin Cancer
Res. 20:3569–3580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Takeshita T, Yamamoto Y, Yamamoto-Ibusuki
M, Inao T, Sueta A, Fujiwara S, Omoto Y and Iwase H: Prognostic
role of PIK3CA mutations of cell-free DNA in early-stage triple
negative breast cancer. Cancer Sci. 106:1582–1589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Black JD, Lopez S, Cocco E, Bellone S,
Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F,
Ferrari F, et al: PIK3CA oncogenic mutations represent a major
mechanism of resistance to trastuzumab in HER2/neu overexpressing
uterine serous carcinomas. Br J Cancer. 113:1020–1026. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Van Keymeulen A, Lee MY, Ousset M, Brohée
S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon
I, et al: Reactivation of multipotency by oncogenic PIK3CA induces
breast tumour heterogeneity. Nature. 525:119–123. 2015. View Article : Google Scholar : PubMed/NCBI
|
